- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04174612
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance (AMELIORATE)
March 1, 2022 updated by: Gruppo Italiano Malattie EMatologiche dell'Adulto
A Phase 3, Prospective, Randomized Multi-center Intervention Trial of Early Intensification in AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance: A MYNERVA-GIMEMA Study
Prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
172
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bari, Italy
- Recruiting
- Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
-
Contact:
- Francesco Albano
- Email: francesco.albano@uniba.it
-
Bari, Italy
- Recruiting
- Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia
-
Bologna, Italy
- Recruiting
- Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia
-
Contact:
- Antonio Curti
- Email: antonio.curti2@unibo.it
-
Brescia, Italy
- Recruiting
- Asst Degli Spedali Civili Di Brescia - Uo Ematologia
-
Contact:
- Chiara Cattaneo
- Email: chiara.cattaneo@libero.it
-
Firenze, Italy
- Recruiting
- Aou Careggi- Sod Ematologia
-
Contact:
- Vannucchi
-
Principal Investigator:
- Alessandro Vannucchi
-
Latina, Italy
- Recruiting
- Asl Latina, Presidio Ospedaliero Nord - Ospedale Santa Maria Goretti - Uoc Ematologia
-
Contact:
- Giuseppe U Cimino
- Phone Number: 3495378159
- Email: cimino@bce.uniroma1.it
-
Lecce, Italy
- Recruiting
- Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia
-
Mestre, Italy
- Recruiting
- Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia
-
Orbassano, Italy
- Recruiting
- Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia
-
Contact:
- Daniela E Cilloni
- Phone Number: 3332818086
- Email: daniela.cilloni@unito.it
-
Palermo, Italy
- Recruiting
- Aou Policlinico P. Giaccone - Palermo - Uo Ematologia
-
Contact:
- Maria Enza U Mitra
- Email: memitra@yahoo.com
-
Palermo, Italy
- Recruiting
- Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo
-
Contact:
- Antonino C Mulè
- Email: a.mule@villasofia.it
-
Pavia, Italy
- Recruiting
- Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia
-
Contact:
- Patrizia U Zappasodi
- Email: p.zappasodi@smatteo.pv.it
-
Ravenna, Italy
- Recruiting
- Ausl Della Romagna, Ospedale "Santa Maria Delle Croci" - Ravenna - Ematologia
-
Reggio Calabria, Italy
- Recruiting
- Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Po E. Morelli - Reggio Calabria - Uoc Ematologia
-
Contact:
- Bruno Marino Martino
- Phone Number: 3489335096
- Email: brunmartin54@gmail.com
-
Reggio Emilia, Italy
- Recruiting
- Ausl Di Reggio Emilia - Arcispedale Santa Maria Nuova, Irccs - Sc Ematologia
-
Contact:
- Alessia S Tieghi
- Email: alessia.tieghi@ausl.re.it
-
Rionero In Vulture, Italy
- Recruiting
- C.R.O.B. - I.R.C.C.S. - Rionero in Volture - Uoc Ematologia
-
Contact:
- Giuseppe U Pietrantuono
- Email: giuseppe.pietrantuono@crob.it
-
Roma, Italy
- Recruiting
- Aou Policlinico Tor Vergata - Roma - Uoc Trapianto Cellule Staminali
-
Siena, Italy
- Recruiting
- Aou Senese - Uoc Ematologia E Trapianti
-
Contact:
- Monica Bocchia
- Email: bocchia@unisi.it
-
Torino, Italy
- Recruiting
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2
-
Contact:
- Ernesta E Audisio
- Email: eaudisio@cittadellasalute.to.it
-
Torino, Italy
- Recruiting
- Ospedale Mauriziano Umberto I - Torino - SCDU Ematologia
-
Contact:
- Alessandro Cignetti
- Email: alessandro.cignetti@unito.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with de novo AML, untreated, newly diagnosed, according to WHO 2016 criteria
- Presence of a mutation of FLT3 gene, either ITD and/or TKD
- Adequate availability of diagnostic biologic material for full cytological, cytogenetic, genetic and immunophenotypic disease characterization according to ELN criteria.
- Presence of morphologically identifiable blasts on peripheral blood at diagnosis
- Presence of a Leukemia-associated aberrant immune-phenotype (LAIP) as assessed by MFC (multiparametric flow cytometry) at diagnosis
- Age between 18 and 65 years, included
- ECOG performance status 0-2 or disease-related reversible ECOG 3 score following adequate supportive care.
- Signed written informed consent according to ICH/EU/GCP and national local laws
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia
- Diagnosis of AML with t(8;21)(q22:q22)/RUNX1-RUNX1T1 and t(16;16)(p13:q22) or inversion of chromosome 16 (16)(p13q22)/CBFB-MYH11; in case of suspicion of CBF-related AML due to morphological and/or immunophenotypic features, specific FISH or molecular testing is strongly recommended in accordance with WHO criteria3,157
- Patients with LVEF less than 45% (by echocardiogram or MUGA)
- Pre-existing, uncontrolled pathology such as heart failure (congestive/ischaemic, acute myocardial infarction within the post 3 months, untreatable arrhythmias, NYHA classes III and IV), sever liver disease with total bilirubin ≥2,5 x ULN and/or ALT>3 ULN (unless attributable to AML), acute or chronic pancreatitis, kidney function impairment with serum creatinine ≥2,5 (unless attributable to AML) and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent or to cope with the intended treatment plan. For altered liver, pancreas and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures.
- Uncontrolled bacterial or fungal infections
- QTc >470 msec on screening ECG (Fridericia's formula)
- A history of cancer that is not in remission phase following surgery and/or chemotherapy and/or radiotherapy with life expectancy < 1 year.
- Pregnancy declared by the patient herself. A pregnancy test is performed at diagnosis and, if applicable, before allogeneic HSCT . Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 4 months after the end of treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard clinical treatment
Patients will complete "3+7" + Midostaurin induction course.
|
100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
60 mg/m2/die day 1-3
50 mg/bid day 8-21
|
Experimental: Experimental treatment
The experimental arm will provide 2 main modifications compared to standard: i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status |
60 mg/m2/die day 1-3
50 mg/bid day 8-21
100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event Free Survival
Time Frame: 2,5 years
|
Improvement of outcome measured as event-free survival (EFS) in patients with FLT3+ acute myeloid leukemia who are predicted to have low chemosensitivity, as defined upon the biomarker "peripheral blast clearance (PBC)", following the application of an early intensification of overall treatment, both in induction (high-doses delivery) and in consolidation (allocation to allogeneic transplant) phase, compared with standard regimens
|
2,5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events rate
Time Frame: 2,5 years
|
Adverse events rate according to CTCAE criteria
|
2,5 years
|
Rate of death in aplasia
Time Frame: 2 months
|
rate of death in aplasia
|
2 months
|
Neutrophil recovery
Time Frame: 2 months
|
Median number of days for neutrophil recovery
|
2 months
|
platelet recovery
Time Frame: 2 months
|
Median number of days for platelet recovery
|
2 months
|
CR rate
Time Frame: 6 months
|
Complete remission rate after induction
|
6 months
|
DFS
Time Frame: 2 years
|
Disease-free survival
|
2 years
|
OS
Time Frame: 2 years
|
Overall survival
|
2 years
|
CIR
Time Frame: 2 years
|
Cumulative incidence of relapse
|
2 years
|
MRD assessment
Time Frame: 6 months
|
MRD negativity rate at the end of induction and consolidation
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 24, 2020
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
August 1, 2025
Study Registration Dates
First Submitted
November 11, 2019
First Submitted That Met QC Criteria
November 20, 2019
First Posted (Actual)
November 22, 2019
Study Record Updates
Last Update Posted (Actual)
March 2, 2022
Last Update Submitted That Met QC Criteria
March 1, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Cytarabine
- Daunorubicin
- Midostaurin
Other Study ID Numbers
- AML1919
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia With FLT3/ITD Mutation
-
H. Lee Moffitt Cancer Center and Research InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia With FLT3/ITD MutationUnited States
-
The First Affiliated Hospital of Soochow UniversityUnknown
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedSecondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With Gene Mutations | FLT3 Tyrosine Kinase Domain Point MutationUnited States
-
Shijiazhuang Yiling Pharmaceutical Co. LtdNot yet recruitingAcute Myeloid Leukemia With FLT3/ITD Mutation
-
Nanfang Hospital of Southern Medical UniversityXiangya Hospital of Central South University; Peking University People's Hospital and other collaboratorsCompletedAcute Myeloid Leukemia | Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
Nanfang Hospital of Southern Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
Nanfang Hospital of Southern Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
National Cancer Institute (NCI)CompletedTherapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | FLT3 Gene Mutation | Acute Promyelocytic Leukemia With PML-RARA | Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1United States
-
Uma BorateRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia With FLT3/ITD MutationUnited States
Clinical Trials on Cytarabine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Jianxiang WangUnknownAcute Myeloid LeukemiaChina
-
Sunesis PharmaceuticalsCompletedAcute Myeloid LeukemiaUnited States, Canada, Spain, Belgium, Korea, Republic of, Australia, France, Germany, Poland, New Zealand, United Kingdom, Czechia, Austria, Hungary, Italy
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent DiseaseUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Roswell Park Cancer InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene MutationsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated CellsUnited States
-
Fred Hutchinson Cancer CenterJazz PharmaceuticalsTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid NeoplasmUnited States